Related Experiment Video
Updated: Jul 18, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Delays to reperfusion therapy in acute ST-segment elevation myocardial infarction: results from the AMI-QUEBEC Study
Thao Huynh1, Jennifer O'Loughlin, Lawrence Joseph
1Division of Cardiology, Department of Cardiology, Montreal General Hospital, Montréal, Quebec, Canada. thao.huynhthanh@mail.mcgill.ca
Insights
Many ST-segment elevation myocardial infarction (STEMI) patients in Quebec experienced delays in reperfusion therapy in 2003. Reorganizing care could reduce these delays for better outcomes.
Area of Science:
- Cardiology
- Public Health
- Health Services Research
Background:
- The AMI-QUEBEC Study investigated delays in reperfusion therapy for ST-segment elevation myocardial infarction (STEMI).
- Identifying factors contributing to prolonged treatment delays was a key objective.
Purpose of the Study:
- To describe the extent of delays in reperfusion therapy for STEMI patients in Quebec.
- To identify patient and system factors associated with prolonged treatment delays.
Main Methods:
- Retrospective chart review of STEMI patients admitted to 17 Quebec hospitals in 2003.
- Data collection focused on time from presentation to reperfusion therapy, analyzing 1189 patients.
Main Results:
- Median delays varied: 32 minutes for fibrinolysis, 109 minutes for primary PCI at the initial hospital, and 142 minutes for primary PCI after transfer.
- Patients presenting outside working hours, receiving primary PCI, or requiring interhospital transfer faced longer delays.
- Increased age was linked to delays only in fibrinolytic therapy patients.
Conclusions:
- A significant proportion of STEMI patients in Quebec did not receive timely reperfusion therapy in 2003.
- Reorganizing pre-hospital and in-hospital care pathways is crucial to expedite reperfusion therapy for STEMI.
Background:
Through the AMI-QUEBEC Study we sought to describe delays to reperfusion therapy for ST-segment elevation myocardial infarction (STEMI) and to identify factors associated with prolonged delays.
Methods:
We reviewed the charts of all consecutive patients with STEMI admitted to 17 hospitals in the province of Quebec in 2003 to obtain data on the time from presentation to reperfusion therapy. Data were available for 1189 (83.0%) of 1432 patients.
Results:
The median delay to reperfusion therapy was 32 minutes (first and third quartile [Q1, Q3] 20, 49) for 535 patients who received fibrinolytic therapy, 109 minutes (Q1, Q3 79, 150) for 455 patients who underwent primary percutaneous coronary intervention (PCI) at the initial hospital of presentation and 142 minutes (Q1, Q3 115, 194) for 199 patients who underwent primary PCI after an interhospital transfer. Patients who presented outside daytime working hours, those who received primary PCI and those who required interhospital transfer for primary PCI were less likely to receive reperfusion therapy within current recommended times (odds ratios [ORs] 0.49, 0.56 and 0.15, respectively). Increased age was associated with prolonged delays only among patients who received fibrinolytic therapy (OR for each 10-year increase in age 0.95, 95% credible interval [CrI] 0.93-0.99 for fibrinolytic therapy and 0.99, 95% CrI 0.95-1.05, for primary PCI).
Interpretation:
In 2003, many patients with STEMI in Quebec were not treated within the recommended times. Delays may be reduced by reorganizing pre-and in-hospital care for patients with STEMI to expedite delivery of reperfusion therapy.
More Related Videos
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:15Ischemic Stroke ll: Pathophysiology
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome III: Diagnostic Studies